Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes

Blood

Volumn 105, Issue 6, 2005, Pages 2436-2442

  Biagi, Ettore ^a,b   Dotti, Gianpietro ^a   Yvon, Eric ^a   Lee, Edward ^a   Pule, Martin ^a   Vigouroux, Stephane ^a   Gottschalk, Stephen ^a   Popat, Uday ^a   Rousseau, Raphael ^a   Brenner, Malcolm ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; B7.1 ANTIGEN; CD134 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; GAMMA INTERFERON; GRANZYME B; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 20144377093     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2556     Document Type: Article

References (38)

1. Dilloo D, Brown M, Roskrow M, et al. CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997;90:1927-1933.
2. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101:1133-1141.
3. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand(CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000;96:2917-2924.
4. Takahashi S, Rousseau R, Yotnda P, et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001;12:659-670.
5. Takahashi S, Rousseau R, Yotnda P, et al. Transgenic expression of CD40L and IL-2 induces an autologous immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther. 2001;8:378-387.
6. McLellan AD, Sorg RV, Williams LA, Hart DN. Human dendritic cells activate T lymphocytes via a CD40:CD40 ligand-dependent pathway. Eur J Immunol. 1996;26:1204-1210.
7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
8. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature. 1998;393:478-480.
9. Fujita N, Kagamu H, Yoshizawa H, et al. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol. 2001;167:5678-5688.
10. Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997;8:1935-1943.
11. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by upregulation of CD80 and CD86 costimulatory molecules. Leukemia. 1997;11:572-580.
12. Cardoso AA, Seamon MJ, Afonso HM, et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 1997;90:549-561.
13. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood. 1999;93:1992-2002.
14. Dotti G, Savoldo B, Takahashi S, et al. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells: a model for immunotherapy. Exp Hematol. 2001;29:952-961.
15. Dotti G, Savoldo B, Yotnda P, Donna R, Brenner M. Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood. 2002;100:200-207.
16. Biagi E, Yvon E, Dotti G, et al. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003;14:545-559.
17. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159:3838-3848.
18. Gramaglia I, Weinberg AD, Lemon M, Croft M. OX-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol. 1998;161:6510-6517.
19. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000;165:3043-3050.
20. Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/ memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol. 2001;167:6804-6811.
21. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;8:609-620.
22. Weinberg AD. OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 2002;23:102-109.
23. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004;4:420-431.
24. Gri G, Gallo E, Di Carlo E, Musiani P, Colombo MP. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J Immunol. 2003;170:99-106.
25. Presented at Annual Meeting of the American Society of Hematology; December 4-7, 2004; San Diege, CA.
26. Baba E, Takahashi Y, Lichtenfeld J, et al. Functional CD4 T cells after intercellular molecular transfer of OX40 ligand. J Immunol. 2001;167:875-883.
27. Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell designated MRC-5. Nature. 1970;227:168-170.
28. Yotnda P, Onishi H, Heslop HE, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001;8:930-937.
29. Gauchat JF, Aubry JP, Mazzei G, et al. Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett. 1993;315:259-266.
30. Jedema I, Van Der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103:2677-2682.
31. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
32. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
33. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666-675.
34. Montagna D, Maccario R, Montini E, et al. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors. Exp Hematol. 2003;31:1031-1038.
35. Lu J, Giuntoli RL 2nd, Omiya R, Kobayashi H, Kennedy R, Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002;8:3877-3884.
36. Porakishvili N, Kardavax L, Jewell AP, et al. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica. 2004;89:435-443.
37. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. Costimulation of CD8 T cell responses by OX40. J Immunol. 2004;172:4821-4825.
38. Pan PY, Zang Y, Weber K, Meseck ML, Chen SH. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther. 2002;6:528-536.